Introduction: Monoclonal antibodies are drugs of biological origin, which are prescribed mostly for diseases of the central nervous system, however,What are the prescribed daily doses of some monoclonal antibodies from patients in the city of Bogotá D.C.? Methodology: This is a descriptive cross-sectional study that uses information on monoclonal antibody prescriptions in the city of Bogotá DC from 2011 to 2017. It is included in the type of drug use studies and adopts the methodology included by the Ministry of Health for studies on the use of prescription medications (38). Results and discussion: We obtained 4775 patients who had the complete dosage regimen of 6 monoclonal antibodies: Adalimumab, Golimumab, Natalizumab, Rituximab, Secukinumab and Ustekinumab. It was found that Adalimumab was the most prescribed with 72.86% (n = 3479), followed by Golimumab with 11.87% (n = 567), Natalizumab with 5.68% (n = 271), Secukinumab with the 4.61% (n = 220), Ustekinumab with 2.81% (n = 134) and finally the Rituximab with 2.18% (n = 104). There was also evidence of 1 case in which Adalimumab was administered for an indication that is not approved by INVIMA "uses not included in the sanitary registry" (UNIRS). Conclusions: A total of 4775 patients were included in the study, in a frequency of 48 to 57 years, 26.97% (n = 1288), and the female sex predominated with 68.21% (n = 3257).